The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection
Abstract
Purpose: To investigate the prognostic value of tumor-infiltrating lymphocytes (TILs), especially regulatory T cells (Tregs), in hepatocellular carcinoma (HCC) patients after resection. Patients and Methods: CD3+, CD4+, CD8+, Foxp3-positive, and granzyme B-positive TILs were assessed by immunohistochemistry in tissue microarrays containing HCC from 302 patients. Prognostic effects of low- or high-density TIL subsets were evaluated by Cox regression and Kaplan-Meier analysis using median values as cutoff. Results: CD3+, CD4+, CD8+ TILs were associated with neither overall survival (OS) nor disease-free survival (DFS). The presence of low intratumoral Tregs in combination with high intratumoral activated CD8+ cytotoxic cells (CTLs), a balance toward CTLs, was an independent prognostic factor for both improved DFS (P = .001) and OS (P < .0001). Five-year OS and DFS rates were only 24.1% and 19.8% for the group with intratumoral high Tregs and low activated CTLs, compared with 64.0% and 59.4% for the group with intratumoral low Tregs and high activated CTLs, respectively. Either intratumoral Tregs alone (P = .001) or intratumoral activated CTLs (P = .001) alone is also an independent predictor for OS. In addition, high Tregs density was associated with both absence of tumor encapsulation (P = .032) and presence of tumor vascular invasion (P = .031). Conclusion: Tregs are associated with HCC invasiveness, and intratumoral balance of regulatory and cytotoxic T cells is a promising independent predictor for recurrence and survival in HCC. A combination of depletion of Tregs and concomitant stimulation of effector T cells may be an effective immunotherapy to reduce recurrence and prolong survival after surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Dannull, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25947 · Cited by 989
Budhu, A., Forgues, M., Ye, Q.-H., Jia, H.-L., He, P., Zanetti, K. A., Kammula, U. S., Chen, Y., Qin, L.-X., Tang, Z.-Y., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.016 · Cited by 846
Self-citationQuezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“Manipulating an increase in the intratumoral ratio of effector to regulatory T cells in poorly immunogenic mice melanoma can overcome Treg-mediated suppression and tip the balance toward tumor rejection.(31) Therefore, a combination of depletion or attenuation of Tregs and concomitant stimulation of tumor-specific eff…”
BackgroundOrmandy, L. A., Hillemann, T., Wedemeyer, H., Manns, M. P., Greten, T. F., & Korangy, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3232 · Cited by 642
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639
Cited by
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T., & Nijman, H. W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.189 · Cited by 1,277
Shang, B., Liu, Y., Jiang, S.-J., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep15179 · Cited by 985
Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., & Iacopetta, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7229 · Cited by 991
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Huang, X.-W., Wang, Z., Chen, E.-B., Fan, J., Cao, Y., Dai, Z., & Zhou, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.040 · Cited by 852
Self-citationGao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
Self-citationHendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès-Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 602
Digital pathology and artificial intelligence in translational medicine and clinical practice
Baxi, V., Edwards, R., Montalto, M., & Saha, S. (2022) · Modern Pathology · doi:10.1038/s41379-021-00919-2 · Cited by 592
Zhu, X.-D., Zhang, J.-B., Zhuang, P.-Y., Zhu, H.-G., Zhang, W., Xiong, Y.-Q., Wu, W.-Z., Wang, L., Tang, Z.-Y., & Sun, H.-C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6521 · Cited by 556
Self-citationCD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
Immune checkpoints and their inhibition in cancer and infectious diseases
Dyck, L., & Mills, K. H. G. (2017) · European Journal of Immunology · doi:10.1002/eji.201646875 · Cited by 541
Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01796-8 · Cited by 545
Self-citationZhang, J.-P., Yan, J., Xu, J., Pang, X.-H., Chen, M.-S., Li, L., Wu, C., Li, S.-P., & Zheng, L. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.033 · Cited by 535
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 513
Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496
Disis, M. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2146 · Cited by 489
deLeeuw, R. J., Kost, S. E., Kakal, J. A., & Nelson, B. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3216 · Cited by 437
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Zhou, G., Sprengers, D., Boor, P. P. C., Doukas, M., Schutz, H., Mancham, S., Pedroza-Gonzalez, A., Polak, W. G., de Jonge, J., Gaspersz, M., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.017 · Cited by 412
Capece, D., Fischietti, M., Verzella, D., Gaggiano, A., Cicciarelli, G., Tessitore, A., Zazzeroni, F., & Alesse, E. (2013) · BioMed Research International · doi:10.1155/2013/187204 · Cited by 408
The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets
Yang, J. D., Nakamura, I., & Roberts, L. R. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.007 · Cited by 390
Fu, Y., Liu, S., Zeng, S., & Shen, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1396-4 · Cited by 390
Wu, K., Kryczek, I., Chen, L., Zou, W., & Welling, T. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0901 · Cited by 380
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07003-x · Cited by 386
Remark, R., Alifano, M., Cremer, I., Lupo, A., Dieu-Nosjean, M.-C., Riquet, M., Crozet, L., Ouakrim, H., Goc, J., Cazes, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3847 · Cited by 375
Bremnes, R. M., Al-Shibli, K., Donnem, T., Sirera, R., Al-Saad, S., Andersen, S., Stenvold, H., Camps, C., & Busund, L.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182037b76 · Cited by 369
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Schwabe, R. F., & Greten, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.016 · Cited by 363
Ma, J., Zheng, B., Goswami, S., Meng, L., Zhang, D., Cao, C., Li, T., Zhu, F., Ma, L., Zhang, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0814-7 · Cited by 360
Self-citationTumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma
Han, S., Zhang, C., Li, Q., Dong, J., Liu, Y., Huang, Y., Jiang, T., & Wu, A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.162 · Cited by 355
Jochems, C., & Schlom, J. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011007 · Cited by 353
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 352
Jiang, R., Tang, J., Chen, Y., Deng, L., Ji, J., Xie, Y., Wang, K., Jia, W., Chu, W.-M., & Sun, B. (2017) · Nature Communications · doi:10.1038/ncomms15129 · Cited by 343
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338
Kimura, T., Kato, Y., Ozawa, Y., Kodama, K., Ito, J., Ichikawa, K., Yamada, K., Hori, Y., Tabata, K., Takase, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13806 · Cited by 336
Frey, D. M., Droeser, R. A., Viehl, C. T., Zlobec, I., Lugli, A., Zingg, U., Oertli, D., Kettelhack, C., Terracciano, L., & Tornillo, L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24989 · Cited by 333
Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
Heimberger, A. B., Abou-Ghazal, M., Reina-Ortiz, C., Yang, D. S., Sun, W., Qiao, W., Hiraoka, N., & Fuller, G. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0320 · Cited by 332
Ladoire, S., Martin, F., & Ghiringhelli, F. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1046-y · Cited by 331
Sinicrope, F. A., Rego, R. L., Ansell, S. M., Knutson, K. L., Foster, N. R., & Sargent, D. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.053 · Cited by 329
Cancer and Inflammation: Promise for Biologic Therapy
Demaria, S., Pikarsky, E., Karin, M., Coussens, L. M., Chen, Y.-C., El-Omar, E. M., Trinchieri, G., Dubinett, S. M., Mao, J. T., Szabo, E., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32e74 · Cited by 325
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer
Lee, H. E., Chae, S. W., Lee, Y. J., Kim, M. A., Lee, H. S., Lee, B. L., & Kim, W. H. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604738 · Cited by 302
Liu, F., Lang, R., Zhao, J., Zhang, X., Pringle, G. A., Fan, Y., Yin, D., Gu, F., Yao, Z., & Fu, L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1647-3 · Cited by 301
Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Greten, T. F., Lai, C. W., Li, G., & Staveley-O’Carroll, K. F. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.09.051 · Cited by 294
The yin and yang of evasion and immune activation in HCC
Makarova-Rusher, O. V., Medina-Echeverz, J., Duffy, A. G., & Greten, T. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.038 · Cited by 293
Yang, X., Liang, L., Zhang, X.-F., Jia, H.-L., Qin, Y., Zhu, X.-C., Gao, X.-M., Qiao, P., Zheng, Y., Sheng, Y.-Y., et al. (2013) · Hepatology · doi:10.1002/hep.26305 · Cited by 280
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
Ding, Z.-B., Shi, Y.-H., Zhou, J., Qiu, S.-J., Xu, Y., Dai, Z., Shi, G.-M., Wang, X.-Y., Ke, A.-W., Wu, B., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1573 · Cited by 273
Self-citationYang, X.-R., Xu, Y., Yu, B., Zhou, J., Qiu, S.-J., Shi, G.-M., Zhang, B.-H., Wu, W.-Z., Shi, Y.-H., Wu, B., et al. (2010) · Gut · doi:10.1136/gut.2008.176271 · Cited by 270
Self-citationResistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight
Lohitesh, K., Chowdhury, R., & Mukherjee, S. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0538-7 · Cited by 270
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
Self-citationIntratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection
Li, Y.-W., Qiu, S.-J., Fan, J., Zhou, J., Gao, Q., Xiao, Y.-S., & Xu, Y.-F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.044 · Cited by 268
Self-citationChew, V., Tow, C., Teo, M., Wong, H. L., Chan, J., Gehring, A., Loh, M., Bolze, A., Quek, R., Lee, V. K. M., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.07.013 · Cited by 259
Zhou, J., Ding, T., Pan, W., Zhu, L., Li, L., & Zheng, L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24556 · Cited by 256
Self-citationLymphocytes in cancer development: Polarization towards pro-tumor immunity
Ruffell, B., DeNardo, D. G., Affara, N. I., & Coussens, L. M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.002 · Cited by 253
Tao, H., Mimura, Y., Aoe, K., Kobayashi, S., Yamamoto, H., Matsuda, E., Okabe, K., Matsumoto, T., Sugi, K., & Ueoka, H. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.002 · Cited by 253
Shimizu, K., Nakata, M., Hirami, Y., Yukawa, T., Maeda, A., & Tanemoto, K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d60fd7 · Cited by 244
Liu, S., Foulkes, W. D., Leung, S., Gao, D., Lau, S., Kos, Z., & Nielsen, T. O. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0432-8 · Cited by 236
Targeting regulatory T cells in tumors
Liu, C., Workman, C. J., & Vignali, D. A. A. (2016) · The FEBS Journal · doi:10.1111/febs.13656 · Cited by 228
Immune system: a double-edged sword in cancer
Lakshmi Narendra, B., Eshvendar Reddy, K., Shantikumar, S., & Ramakrishna, S. (2013) · Inflammation Research · doi:10.1007/s00011-013-0645-9 · Cited by 206
Song, G., Shi, Y., Zhang, M., Goswami, S., Afridi, S., Meng, L., Ma, J., Chen, Y., Lin, Y., Zhang, J., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-00214-5 · Cited by 175
Self-citationTanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138
Faget, J., Biota, C., Bachelot, T., Gobert, M., Treilleux, I., Goutagny, N., Durand, I., Léon-Goddard, S., Blay, J. Y., Caux, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0573 · Cited by 129
Turcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C. S., Wunderlich, J. R., Dudley, M. E., & Rosenberg, S. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300538 · Cited by 107
Liu, X., Xu, D., Huang, C., Guo, Y., Wang, S., Zhu, C., Xu, J., Zhang, Z., Shen, Y., Zhao, W., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1929-9 · Cited by 53
Efferocytosis Creates a Tumor Microenvironment Supportive of Tumor Survival and Metastasis
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.666 · Cited by 44
The appearance of Tregs in cancer nest is a promising independent risk factor in colon cancer
Xu, W., Liu, H., Song, J., Fu, H.-X., Qiu, L., Zhang, B.-F., Li, H.-Z., Bai, J., & Zheng, J.-N. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1500-7 · Cited by 31
Malczewski, A. B., Ketheesan, N., Coward, J. I. G., & Navarro, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624434 · Cited by 22
Metadata
- Authors
- Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-06-20
- Volume
- 25
- Issue
- 18
- Pages
- 2586-2593
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2122656254
- Cited by
- 1,110
- References
- 31
- FWCI
- 30.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.